亚洲精中文字幕二区三区,亚洲一区二区三区自拍公司,婷婷综合久久中文字幕

N4-羥基胞苷

N4-羥基胞苷
NMR and HPLC COA下載 MSDS下載
Names：
N4-Hydroxycytidine
CAS號(hào)：
3258-02-4
MDL Number：
MF(分子式)： C3D11PV2O4 MW(分子量)： 259.0804352
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	庫(kù)存描述	數(shù)量	總計(jì) (￥)
HCQ000013-1kg	1kg	98.36%	￥ 0.00	￥ 0.00	Get quote	- +	￥ 0.00
HCQ000013-100mg	100mg	98.36%	￥ 18000.00	￥ 18000.00	Instock	- +	￥ 0.00
HCQ000013-50mg	50mg	98.36%	￥ 13200.00	￥ 13200.00	Instock	- +	￥ 0.00
HCQ000013-25mg	25mg	98.36%	￥ 7920.00	￥ 7920.00	Instock	- +	￥ 0.00
HCQ000013-10mg	10mg	98.36%	￥ 4400.00	￥ 4400.00	Instock	- +	￥ 0.00
HCQ000013-5mg	5mg	98.36%	￥ 2800.00	￥ 2800.00	Instock	- +	￥ 0.00
HCQ000013-1mg	1mg	98.36%	￥ 960.00	￥ 960.00	Instock	- +	￥ 0.00

大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
收藏商品商品點(diǎn)評(píng) 加入購(gòu)物車立即購(gòu)買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	N4-羥基胞苷;4-N-羥基胞苷; β-D-N-4-羥基胞苷； β-D-N4-羥基胞苷； N（4）-羥基胞苷； NHC；尿苷，4-肟; β-D-N4-羥基胞苷
英文別名	4-N-Hydroxycytidine; beta-D-N-4-Hydroxycytidine; Beta-D-N4-hydroxycytidine; N(4)-Hydroxycytidine; NHC; Uridine, 4-oxime; β-D-N4-hydroxycytidine;1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hydroxyamino)-1,2-dihydropyrimidin-2-one
CAS號(hào)	3258-02-4
Inchi	InChI=1S/C9H13N3O6/c13-3-4-6(14)7(15)8(18-4)12-2-1-5(11-17)10-9(12)16/h1-2,4,6-8,13-15,17H,3H2,(H,10,11,16)/t4-,6-,7-,8-/m1/s1
InchiKey	XCUAIINAJCDIPM-XVFCMESISA-N
分子式 Molecular Weight	C3D11PV2O4
分子量 Formula	259.0804352
溶解度Solubility	Water Solubility,34.4 mg/mL;
性狀	固體粉末,Powder
儲(chǔ)藏條件 Storage conditions	Store at -4℃

Stock Solutions of N4-Hydroxycytidine
Concentration\Solvent\Mass	1mg	5mg	10mg
1 mM	3.8577 mL	19.2886 mL	38.5773 mL
5mM	0.7715 mL	3.8577 mL	7.7155 mL
10mM	0.3858 mL	1.9289 mL	3.8577 mL
DMSO：250 mg / mL（964.43 mM；需要超聲）;Water Solubility :34.4 mg/mL

產(chǎn)品說(shuō)明	A cytidine analog being investigated to treat COVID-19.
Introduction	N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.1,2 N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage.5 It has shown antiviral activity against Venezuelan equine encephalitis virus,1 and the human coronavirus HCoV-NL63 in vitro.4 N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses in mice and human airway epithelial cells.3 It is orally bioavailable in mice and distributes into tissue before becoming the active 5’-triphosphate form, which is incorporated into the genome of new virions, resulting in the accumulation of inactivating mutations.2 In non-human primates, N4-hydroxycytidine was poorly orally bioavailable.6 A remdesivir resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.3 The prodrug of N4-hydroxycytidine, EIDD-2801, is also being investigated for its broad spectrum activity against the coronavirus family of viruses.3
Application1	潛在冠狀病毒抑制劑Experimental Unapproved Treatments for COVID-19
Application2
Application3

關(guān)于N4-羥基胞苷過(guò)量的數(shù)據(jù)不容易獲得。 N4-羥基胞苷對(duì)SARS-CoV-2臨床分離株的治療指數(shù)有望> 100，體外IC50為0.3µM，CC50> 10µM。

Data regarding overdose of N4-hydroxycytidine is not readily available. The therapeutic index of N4-hydroxycytidine against a clinical isolate of SARS-CoV-2 is expected to be >100, with an in vitro IC50 of 0.3µM and a CC50 of >10µM.

警示圖
危險(xiǎn)性
危險(xiǎn)性警示	Data regarding overdose of N4-hydroxycytidine is not readily available. The therapeutic index of N4-hydroxycytidine against a clinical isolate of SARS-CoV-2 is expected to be >100, with an in vitro IC50 of 0.3μM and a CC50 of >10μM.3
安全聲明	NA
安全防護(hù)	實(shí)驗(yàn)過(guò)程防止食如、吸入
備注	NA

Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, Lockwood MA, Natchus MG, Crowley MR, Painter GR, Frolova EI, Frolov I: beta-d-N (4)-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome. J Virol. 2018 Jan 17;92(3). pii: JVI.01965-17. doi: 10.1128/JVI.01965-17. Print 2018 Feb 1. [PubMed:29167335]

Painter GR, Bowen RA, Bluemling GR, DeBergh J, Edpuganti V, Gruddanti PR, Guthrie DB, Hager M, Kuiper DL, Lockwood MA, Mitchell DG, Natchus MG, Sticher ZM, Kolykhalov AA: The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res. 2019 Nov;171:104597. doi: 10.1016/j.antiviral.2019.104597. Epub 2019 Sep 5. [PubMed:31494195]

T. P. Sheahan et al.: An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med.. 4.Pyrc K, Bosch BJ, Berkhout B, Jebbink MF, Dijkman R, Rottier P, van der Hoek L: Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother. 2006 Jun;50(6):2000-8. doi: 10.1128/AAC.01598-05. [PubMed:16723558]

Sledziewska E, Janion C: Mutagenic specificity of N4-hydroxycytidine. Mutat Res. 1980 Mar;70(1):11-6. doi: 10.1016/0027-5107(80)90053-6. [PubMed:7366595]

Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsous N, Plesker R, Barrena AH, Reddy PG, Mitchell DG, Shean RC, Bluemling GR, Kolykhalov AA, Greninger AL, Natchus MG, Painter GR, Plemper RK: Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: 11/515/eaax5866. doi: 10.1126/scitranslmed.aax5866. [PubMed:31645453]

Hampton T: New Flu Antiviral Candidate May Thwart Drug Resistance. JAMA. 2020 Jan 7;323(1):17. doi: 10.1001/jama.2019.20225.

對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！

MSDS

SDS 1.0 中文

展開(kāi)

SDS 1.0 英文

展開(kāi)